Tens of thousands of women forced to travel out of state for abortion care after Roe v Wade was overturned in 2022
One out of every seven abortion patients, or roughly 155,000 people, left their home state for abortion care last year, according to the Guttmacher Institute, a reproductive health research group.
That total is slightly fewer than the 170,000 people who traveled for abortion care in 2023, but it remains a remarkable spike in abortion-related travel compared to the years before the Supreme Court's June 2022 decision in Dobbs v Jackson Women's Health Organization, which overturned Roe v Wade and allowed states to criminalize abortion care and implement outright bans.
Out-of-state travel for abortion care has virtually doubled since that ruling. Since the Dobbs decision, 13 states have outlawed abortions in virtually all circumstances, creating a patchwork of abortion access across the country, and balkanized legal constraints for patients and providers, who are shielded in some states and criminalized in others.
The total number of abortions each year has also steadily increased in the wake of that decision.
In 2024, 1.14 million abortions occurred in the United States, according to the Society for Family Planning.
Roughly one in four abortions were performed through telehealth last year, with an average of 12,330 abortions per month performed through medication abortion, which typically requires a two-drug protocol that a patient can take at home.
That's up from one in five in 2023 and one in every 20 in 2022.
Medication abortion has accounted for the vast majority of abortions in recent years. Roughly 63 percent of all abortions are now medication abortions, according to Guttmacher.
Mifepristone, one of two prescription drugs used in medication abortions, is approved for use by the FDA up to 10 weeks of pregnancy. From 2019 through 2020, nearly 93 percent of all abortions were performed before the 13th week, according to the Centers for Disease Control and Prevention.
But the drug is at the center of legal challenges fueled by right-wing anti-abortion activist groups who have sought to strip the government's approval and implement sweeping federal bans on abortion care.
President Donald Trump's administration has also pledged to revisit the drug's approval, using spurious reporting and junk science, in an apparent attempt to undermine the basis for the government's approval.
Nearly half of patients who traveled for an abortion last year came from states where abortion is outlawed — including more than 28,000 Texas residents, more than any other state, Guttmacher found.
'While these findings show us where and how far patients are traveling, they are not able to capture the numerous financial, logistical, social and emotional obstacles people face,' according to Guttmacher Institute data scientist and study lead Isaac Maddow-Zimet.
In the months after the Dobbs decision, sweeping anti-abortion restrictions across the deep South and neighboring states have effectively forced abortion patients to travel hundreds of miles to reach the nearest state where abortion access was legal.
Florida, surrounded by anti-abortion states, was initially a key point of abortion access in the South within the first two years after the Dobbs decision. In 2023, more than 9,000 people traveled from other states to get an abortion there, according to Guttmacher. Roughly one in every two abortions nationwide and one in three abortions in the South were performed in Florida at that time.
Last year, Florida banned abortion beyond six weeks of pregnancy, before many women know they are even pregnant, and the number of patients traveling to the state for abortion care was virtually cut in half.
Another 8,000 people left the state to get an abortion elsewhere, often crossing as many as three states to get there, Guttmacher found.
'It was not just Floridians who were impacted, but also the thousands of out-of-state patients who would have traveled there for care,' according to Candace Gibson, Guttmacher Institute Director of State Policy.
'The most extreme abortion bans are concentrated in the South, which makes it disproportionately difficult for people living in that region to exercise their fundamental right to bodily autonomy,' she added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
an hour ago
- The Guardian
Pfizer Covid vaccine for young children may not be renewed by FDA
Pfizer's Covid vaccine for young children may not be renewed by the US Food and Drug Administration (FDA) this fall, prompting Moderna to fill possible gaps in supply, according to an email obtained by the Guardian. The move would pull the only remaining Covid vaccine for all children under five from the market. The Moderna vaccine is only approved for children with one or more health conditions, and the pediatric Covid vaccine from Novavax is only available for children aged 12 and up with health conditions. 'It certainly would create a hole in the availability of vaccines,' said Georges Benjamin, the executive director of the American Public Health Association. 'And to do it this late in the season – I think clearly it's inappropriate.' According to an email from the National Center for Immunization and Respiratory Diseases (NCIRD), Pfizer said the FDA recently informed the pharmaceutical company that it may not renew the emergency use authorization for its pediatric Covid vaccine for the 2025 respiratory season. The email was sent on Friday to state and local vaccination grantees. The Pfizer vaccine is given to children between the ages of six months and four years. Pfizer expects its Covid vaccine for children aged five to 11 to be fully licensed this fall, the email said. The Centers for Disease Control and Prevention (CDC) is 'in discussions' with Moderna about rapidly increasing its Covid vaccine supply for young children, according to the email. That includes internal planning about volume, timing, and potential supply gaps. 'We are working to ensure there will be sufficient supply,' said Chris Ridley, a Moderna spokesperson. The CDC, the US Department for Health and Human Services (HHS), and Pfizer did not respond to media inquiries by publication time. In July, Moderna received FDA approval of its Covid pediatric shot. But the vaccine was only approved for children with one or more health conditions that make them more vulnerable to Covid. This move could limit access to Covid vaccines. 'We already have a low number of people using the vaccines to start with,' Benjamin said. 'There hasn't been enough promotion of vaccinations for kids, and then you have Mr [Robert F] Kennedy's [Jr] unscientific statements about the safety and efficacy of vaccines, particularly Covid vaccines, for both pregnant women and kids. It has muddied the waters of what people know about the safety and efficacy of the vaccine.' The vaccine is extremely effective, especially against hospitalization and death. Yet only 5.6% of children aged six months to four years are vaccinated against Covid, and about 15% of children aged five to 17 are vaccinated, according to the CDC. While older adults have the highest rates of hospitalization and death, children continue seeing hospitalization rates from Covid similar to rates in 2020 and 2021. And there are other concerns with Covid infection. 'We don't know the long-term impact for kids who have gotten Covid as a disease. We do know it does cause a multi-systemic inflammatory process in a number of kids, which is very severe, and we don't know the long-term implications for long Covid in kids,' Benjamin said. Covid cases are rising in many parts of the US amid other vaccine restrictions proposed and implemented by health officials.
The Guardian
4 hours ago
- The Guardian
Vinay Prasad returns to FDA days after leaving under pressure from Laura Loomer
Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the US Food and Drug Administration (FDA) a little more than a week after he left the agency. 'At the FDA's request, Dr Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' Department Health and Human Services spokesperson Andrew Nixon said in a statement to Reuters. Prasad left the agency on 30 July after just a few months as director of the center. Endpoints News, which covers the biotech industry, first reported the return of Prasad. Prasad, an oncologist who was a fierce critic of US Covid-19 vaccine and mask mandates, was named the center's director by the FDA's commissioner, Marty Makary, in May. Criticism of Prasad's tenure intensified around the agency's handling of a gene therapy for Duchenne muscular dystrophy (DMD) from Sarepta Therapeutics. The FDA-approved therapy played a role in the death of two teens who had advanced DMD. After a third death in a separate experimental gene therapy from the company, the FDA asked Sarepta on 18 July to stop all shipments of the approved DMD therapy, saying it had safety concerns. The FDA changed course on Sarepta on 28 July and said shipments to the main group of patients for the drug could restart. Laura Loomer, a far-right influencer and conspiracy theorist with outsized sway over Donald Trump, had called Prasad a 'progressive leftist saboteur' who was undermining the agency's work. Two days before Prasad stepped down last month, Loomer had released misleadingly edited audio to suggest that that Prasad had admitted sticking pins in a Trump voodoo doll, when the full audio made it clear that he was talking about the kind of thing an imagined liberal Trump-hater would do. Loomer reacted to the news of Prasad's return on Saturday by renewing her attacks on him in a social media post in which she promised to produce 'exposes of officials within HHS and FDA' in the weeks ahead. 'There are several Senate Confirmation hearings coming up and I have multiple oppo books ready for distribution!' she wrote. Prasad was a physician who joined the agency from the University of California, San Francisco. He has had stints at the National Cancer Institute and the National Institutes of Health. The FDA and other health agencies have seen multiple shake-ups in recent months under the leadership of health secretary Robert F Kennedy Jr.
The Guardian
6 hours ago
- The Guardian
Vinay Prasad returns to FDA days after leaving under pressure from Laura Loomer
Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the US Food and Drug Administration (FDA) a little more than a week after he left the agency. 'At the FDA's request, Dr Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' Department Health and Human Services spokesperson Andrew Nixon said in a statement to Reuters. Prasad left the agency on 30 July after just a few months as director of the center. Stat News first reported the return of Prasad. Prasad, an oncologist who was a fierce critic of US Covid-19 vaccine and mask mandates, was named the center's director by the FDA's commissioner, Marty Makary, in May. Criticism of Prasad's tenure intensified around the agency's handling of a gene therapy for Duchenne muscular dystrophy (DMD) from Sarepta Therapeutics. The FDA-approved therapy played a role in the death of two teens who had advanced DMD. After a third death in a separate experimental gene therapy from the company, the FDA asked Sarepta on 18 July to stop all shipments of the approved DMD therapy, saying it had safety concerns. The FDA changed course on Sarepta on 28 July and said shipments to the main group of patients for the drug could restart. Laura Loomer, a far-right influencer and conspiracy theorist with outsized sway over Donald Trump, had called Prasad a 'progressive leftist saboteur' who was undermining the agency's work. Two days before Prasad stepped down last month, Loomer had released misleadingly edited audio to suggest that that Prasad had admitted sticking pins in a Trump voodoo doll, when the full audio made it clear that he was talking about the kind of thing an imagined liberal Trump-hater would do. Loomer reacted to the news of Prasad's return on Saturday by renewing her attacks on him in a social media post in which she promised to produce 'exposes of officials within HHS and FDA' in the weeks ahead. 'There are several Senate Confirmation hearings coming up and I have multiple oppo books ready for distribution!' she wrote. Prasad was a physician who joined the agency from the University of California, San Francisco. He has had stints at the National Cancer Institute and the National Institutes of Health. The FDA and other health agencies have seen multiple shake-ups in recent months under the leadership of health secretary Robert F Kennedy Jr.
